INTRODUCTION

Asthma is a common disease of airways characterized by chronic inflammation and usually presents with symptoms like shortness of breath, cough, chest tightness and wheezing and these symptoms do vary over time in intensity. Asthma has a great global impact. Estimated prevalence of Asthma in Pakistan as highlighted by report on Global burden of Asthma is 4.3%. There are multiple factors that trigger asthma symptoms which include allergen exposure, smoking, allergic rhinitis, sinusitis, gastroesophageal reflux disease (GERD), inadequate use of inhaled corticosteroid (ICS) that include poor adherence to medication and inappropriate inhaler technique. Asthma has a great impact on population and when poorly controlled leads to considerable economic impact with loss of work days, school attendance, frequent hospital admissions, poor quality of life and ultimately death. According to a study, approximately 24.2% of the patients with asthma have well controlled asthma. There are multiple studies from different parts of the world that reflect asthma control and also the influence of these factors over symptom control but no such study has been conducted in Pakistan. Therefore, the objective behind conducting this study was to assess the level of symptoms control achieved by asthmatic patients in Pakistan and to assess the factors which are making an impact on symptom control so that these factors can be focused and managed effectively in order to achieve good control over symptoms and lead a healthy life.

METHODS

A prospective cross sectional study was undertaken at Darul Sehat Hospital for duration of December 2018 till December 2019 after Institutional Review Board (IRB) approval. Taking frequency of asthma control as 24.2%, confidence interval (CI) as 95% and precision as 8%, the estimated sample size came out to be 111 but total 113 patients were included. Non Probability Consecutive sampling technique was used for sample collection. Both male and female patients of either age, presenting with respiratory symptoms such as cough, shortness of breath, chest tightness and wheezing and were diagnosed as having bronchial asthma by physician on the basis of appropriate clinical history and examination or proved by spirometry were included. Patients were excluded if they refused to give consent, had clinical features that suggested other diagnoses.
on treatment of pulmonary tuberculosis or previously treated for pulmonary tuberculosis, or had severe exacerbation requiring hospitalization. Written informed consent was obtained from all patients after explaining pros and cons of the study. Patients fulfilling inclusion criteria were interviewed. Demographic data including age, gender, height, weight, comorbid conditions such as diabetes mellitus, hypertension, ischemic heart disease, smoking status, time since asthma diagnosis, family history of asthma, history of atopy (self-reported history of allergic rhinitis or eczema and occupation were noted. Symptom control was assessed according to Global Initiative for Asthma (GINA) symptom control assessment tool. (Table 1) This tool comprise frequency of symptoms reported in daytime, night awakening due to asthma, any activity limitation as a result of asthma, and number of times reliever medication taken per week over the period of 4 weeks. Symptom control was labeled as “well controlled” if all of these features were absent. In the presence of 1 or 2 features, symptom control was labeled as “partially controlled”. If 3 or more of these features were present then symptom control was labeled as “uncontrolled”. Record of current medications in patient’s use was obtained by either seeing prescription of patients own chest physician or patient showing medicines at the time of interview. Presence of different risk factors was also noted. GERD was recorded as self-reported sensation of retrosternal burning requiring medication. Allergic rhinitis was recorded as self-reported recurrent episodes of nasal discharge and sneezing related to allergen exposure or seasonal change. Asthma exacerbations were defined as worsening of symptoms requiring addition of a course of oral corticosteroids, according to the recommendation of patient’s own chest physician. The number of asthma exacerbations experienced over past 12 months was retrospectively assessed by asking the patients the number of times patient needed to modify usual treatment or had to take courses of oral corticosteroids. Eosinophil counts were recorded from patients’ complete blood count (CBC). Exposure to the occupational agents leading to development of symptoms and the use of drugs that may precipitate symptoms such as salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs) or beta-blockers were also noted as potential asthma triggering factors. Patient’s current medications were also noted. High use of reliever medicine was assessed by asking the patient about consumption of short acting beta agonist (SABA) inhaler within 1 month. Inadequate use of inhaled corticosteroids was assessed by presence of either of the following: Not ever prescribed or poor compliance or incorrect inhaler technique. Inhaler technique for the use of a metered-dose or dry powder inhaler was evaluated by the investigator by asking the patients to demonstrate their usual inhaler technique and recorded as incorrect or correct according to previously reported evaluation of inhaler use. Respiratory infections were defined as self-reported episodes of increasing cough and purulent sputum for which a course of antibiotic medications was prescribed to the patient by the primary chest physician. Data entry and analysis was done using statistical package for social sciences (SPSS) version 22.0. All qualitative variables were expressed in terms of frequency and percentages While all quantitative variables were expressed in terms of mean and standard deviation (SD). Prevalence of different levels of symptom control in asthma patients was also calculated. Effects modifiers were controlled by stratification to see their effect on poor symptom control in asthma patients. Chi-square test/Fisher-exact was applied and p value of ≤0.05 was taken as significant.

Table 1: Asthma control according to Global Initiative for Asthma (GINA) for adults

| Symptoms in the past 4 weeks | Asthma symptom control |
|-----------------------------|------------------------|
|                             | Well Controlled        | Partly Controlled | Uncontrolled |
| Daytime symptoms more than 2×/week | No criterion applies | 1–2 criteria apply | 3–4 criteria apply |
| Nocturnal awakening due to asthma at any time |                             |                   |
| Reliever >2×/week Any limitation of daily activity due to asthma |                             |                   |
RESULTS

Total 113 patients were included in this study. Mean age of the patients was 36.8 ± 16.6 years. Mean duration of asthma was 18.0 ± 12.0 years. Family history of asthma was positive in 82 (72.6%). Among co-morbid conditions, hypertension was common and was present in 23 (20.4%) of the patients. Among presenting symptoms, shortness of breath was the most common symptom and was present in 111 (98.2%) patients. Chest tightness was present in all patients. Among patients with atopy, allergic rhinitis was present in 108 (95.6%) patients. Total 68 (60.2%) had greater than 1 episode of asthma exacerbation in last 12 months. Total 35 (31.0%) were smokers and 78 (69.0%) were nonsmokers. All the patients used inhalers and among them, 108 (95.6%) had the incorrect technique of using inhaler. Total 85 (75.2%) had gastroesophageal reflux disease (GERD). Moreover, uncontrolled asthma was present in 76 (67.3%) of the cases.

Among patients taking medications for asthma, short acting beta agonist (SABA) was used by 97 (85.8%) patients, inhaled corticosteroid (ICS) was used by 46 (40.7%) patients, long acting beta agonist (LABA) was used by 46 (40.7%) patients and leukotriene receptor agonist (LTRA) was used by 70 (61.9%) patients. Table 2 describes briefly the medications used.

Uncontrolled asthma was significantly higher in patients without any history of diabetes mellitus (p value of 0.002), in patients using inhalers incorrectly (p value of 0.039), in patients with more than 10 years asthma duration (p value <0.001), in patients with GERD (p value <0.001) and in patients having >1 episode of asthma exacerbation in last 12 months (p value <0.001) (Table 3). Uncontrolled asthma was significantly higher in patients not taking ICS (p value <0.001) and in patients with high use of SABA (p value <0.001) (Table 4).

DISCUSSION

Asthma is a major prevalent disease globally accounting for its presence in approximately 300 million people, and is responsible for almost 250,000 deaths prematurely annually. Asthma has a negative impact on the patients as well as their communities by causing loss of work and school hours, impaired quality of life, frequent hospitalizations, frequent visit to the emergency department (ED) and in severe cases death may also occur. A significant portion of costs related to asthma has been attributed to severe as well as uncontrolled asthma. In the present study we determined a developing country’s perspective from Asia for evaluating symptom control in asthmatic patients. Moreover, factors related to poor symptom control in asthma were also assessed.

The results of our study demonstrated a high prevalence of uncontrolled asthma in our population. A high prevalence of uncontrolled asthma has been reported as compared to our study. This could be due to larger sample size of the previous studies. Another study with physician diagnosed asthma demonstrated a high prevalence of uncontrolled asthma. In our study, GINA assessment tool was labeled to evaluate asthma symptom control which yielded high prevalence of uncontrolled asthma, whereas an international study reported a lower prevalence of uncontrolled asthma.

Our study has shown that well controlled asthma has a lower prevalence in our population. This contrasts with the results reported by other authors. Such a difference in results could be due to the reason that these previous studies were conducted on a larger sample size. Moreover, the difference in genetic and ethnic factors between the study populations could be another postulated reason for difference in asthma symptom control.

Table 2: Medication use in study population

| Medication                          | n  | %   |
|-------------------------------------|----|-----|
| Short acting beta agonist (SABA)    | 97 | 85.8|
| High use of SABA                    | 34 | 30.1|
| Inhaled corticosteroid              | 32 | 28.3|
| Long acting beta agonist            | 46 | 40.7|
| Leukotriene receptor agonist        | 70 | 61.9|
| Methylxanthine                      | 3  | 2.7 |
| Long acting muscarinic antagonist   | 2  | 1.8 |
| Nonsteroidal anti-inflammatory drugs| 3  | 2.7 |
| Beta blocker                        | 12 | 10.6|
| Salicylates                         | 1  | 0.9 |

SABA: Short Acting Beta Agonist
A high prevalence of uncontrolled asthma was reported in women in our study. Studies have also reported a higher prevalence of uncontrolled asthma in females.\textsuperscript{16,17} In childhood, asthma has a higher prevalence in boys, but at puberty there is an increase in sex hormones that causes in increase in asthma in females.\textsuperscript{18} Moreover, females have high IgE levels at puberty and this may result in triggering of symptoms by dust or pollen exposure with associated reduced ratio of FEV1/FVC.\textsuperscript{19} In our study, uncontrolled asthma was higher in patients having family history of asthma. An important risk factor of asthma is having its family history and evaluation of familial risk can help identify the patients who have a high risk of asthma. However, a study has shown that patients having family history of asthma have best controlled asthma.\textsuperscript{20} The pathogenesis of asthma involves a complex interaction of various ethnic, genetic and life style factors and this could be the reason behind a varying prevalence of asthma control between these studies.

Our study results reported that patients with uncontrolled asthma had lower incidence of diabetes. Another study has reported that diabetes has not a significantly high prevalence in patients with difficult to treat asthma.\textsuperscript{21} Insulin resistance, metabolic syndrome and diabetes have an important pathophysiological role in development of asthma.\textsuperscript{22}

The results of our study have shown that history of

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|l|l|}
\hline
Factors & Total & Uncontrolled (n=76) & Well/Partially controlled (n=37) & p-value \\
\hline
Diabetes Mellitus & & & & \\
Present & 15 (13.3) & 15 (100) & 0 (0) & 0.002** \\
Absent & 98 (86.7) & 61 (62.2) & 37 (37.8) & \\
\hline
Hypertension & & & & \\
Present & 23 (20.4) & 21 (29.3) & 2 (8.7) & 0.006* \\
Absent & 90 (79.6) & 55 (61.1) & 35 (38.9) & \\
\hline
Inhaler technique & & & & \\
Correct & 5 (4.4) & 1 (20) & 4 (80) & 0.039** \\
Incorrect & 108 (95.6) & 75 (69.4) & 33 (30.6) & \\
\hline
GERD & & & & \\
Present & 85 (75.2) & 65 (76.5) & 20 (23.5) & <0.001* \\
Absent & 28 (24.8) & 11 (39.3) & 17 (60.7) & \\
\hline
Duration of symptoms & & & & \\
≤10 years & 31 (27.4) & 7 (22.6) & 24 (77.4) & <0.001* \\
>10 years & 82 (72.6) & 69 (84.1) & 13 (15.9) & \\
\hline
Number of exacerbations & & & & \\
≤1 & 45 (39.8) & 19 (25) & 26 (70.3) & <0.001* \\
>1 & 68 (60.2) & 57 (75) & 11 (29.7) & \\
\hline
Cough & & & & \\
Absent & 22 (19.5) & 9 (11.8) & 13 (35.1) & 0.003* \\
Present & 91 (80.5) & 67 (88.2) & 24 (64.9) & \\
\hline
Shortness of breath & & & & \\
Absent & 2 (1.8%) & 0 (0) & 2 (5.4) & 0.105 \\
Present & 111 (98.2) & 76 (100) & 35 (94.6) & \\
\hline
Wheezing & & & & \\
Present & 105 (92.9) & 73 (96.1) & 32 (86.5) & 0.111** \\
Absent & 8 (7.1) & 3 (3.9) & 5 (13.5) & \\
\hline
\end{tabular}
\caption{Baseline factors significantly associated with asthma control}
\end{table}

- GERD: Gastroesophageal Reflux Disease
- Following factors were found insignificantly associated with asthma control: Gender (p-value 0.289*), Family history of asthma (p-value 0.703*), Ischemic heart disease (p-value 0.155*), Atopy (p-value 0.155*), Eosinophil count (p-value 0.312*)
- *Chi-square test applied, **Fisher's exact test applied
atopy was higher in patients with uncontrolled asthma as compared with partially controlled/well controlled asthma. Similar results have been shown by a previous study. According to a study, atopic patients usually have onset of asthma at an earlier age; however the study concluded that aeroallergens were not the predictors of asthma control. Among atopy, nasal diseases such as allergic rhinitis or rhinosinusitis are among prevalent chronic respiratory illnesses. Our study has shown that uncontrolled asthma was significantly higher in patients with incorrect inhaler technique. A regional study has reported a similar observation that poorly controlled asthma patients and those patients whose FEV1 is less than 70% have error in their technique of using inhalers. Another study reported a high prevalence of incorrect inhaler technique which reduced at the follow up visit indicating the importance of proper educating regarding the inhaler technique.

According to our study results, patients with uncontrolled asthma had significantly higher GERD. A previous study has shown that in patients with uncontrolled asthma, GERD prevalence was higher. Another study has demonstrated that GERD was the third most common comorbid condition in patients with asthma after rhinitis or sinusitis and cardiovascular diseases. A significantly higher number of patients in our study with uncontrolled asthma had duration of asthma of more than 10 years. Another study also reported a statistically significant difference between duration of asthma and asthma control, with uncontrolled asthma population having a longer

---

Table 4: Comparison of asthma control with medication use

|               | Total | Asthma Symptom Control | p-value |
|---------------|-------|------------------------|---------|
|               |       | Uncontrolled | Well/Partially controlled |
| SABA          |       |             |                     |
| Present       | 97 (85.8) | 67 (88.2) | 30 (81.1) | 0.390* |
| Absent        | 16 (14.2) | 9 (11.8) | 7 (18.9) |
| ICS           |       |             |                     |
| Present       | 32 (28.3) | 15 (19.7) | 17 (45.9) | 0.004* |
| Absent        | 81 (71.7) | 61 (80.3) | 20 (54.1) |
| LABA          |       |             |                     |
| Present       | 46 (40.7) | 35 (46.1) | 11 (29.7) | 0.097* |
| Absent        | 67 (59.3) | 41 (53.9) | 26 (70.3) |
| LTRA          |       |             |                     |
| Present       | 70 (61.9) | 45 (59.2) | 25 (67.6) | >0.999** |
| Absent        | 43 (38.1) | 31 (40.8) | 12 (32.4) |
| LAMA          |       |             |                     |
| Present       | 2 (1.8) | 2 (2.6%) | 0 (0) | >0.999** |
| Absent        | 111 (98.2) | 74 (97.4) | 37 (100) |
| Methylxanthine|       |             |                     |
| Present       | 3 (2.7) | 2 (2.6) | 1 (2.7) | >0.999** |
| Absent        | 110 (97.3) | 74 (97.4) | 36 (97.3) |
| NSAIDs        |       |             |                     |
| Present       | 3 (2.7) | 3 (3.9%) | 0 (0) | 0.550** |
| Absent        | 110 (97.3) | 73 (96.1) | 37 (100) |
| Beta blocker  |       |             |                     |
| Present       | 12 (10.6) | 11 (14.5%) | 1 (2.7) | >0.999** |
| Absent        | 101 (89.4) | 65 (85.5) | 36 (97.3) |
| High use of SABA|      |             |                     |
| Present       | 34 (30.1) | 34 (44.7) | 0 (0) | <0.001* |
| Absent        | 79 (69.9) | 42 (55.3) | 37 (100) |

- ICS: Inhaled Corticosteroid, LABA: Long Acting Beta Agonist, LAMA: Long Acting Muscarinic Antagonist, LTRA: Leukotriene Receptor Agonist. NSAIDs: Nonsteroidal Anti-Inflammatory Drugs, SABA: Short Acting Beta Agonist
- *Chi-square test applied, **Fisher’s exact test applied
asthma duration.\textsuperscript{39} Longer asthma duration has been linked to poor asthma control due to irreversible obstruction to airflow. IgE, cytokines derived from T cells and mast cells start the early asthma reaction whereas activation of eosinophils have their role in persistent asthma symptoms characterizing chronic obstruction to airflow which later becomes irreversible after a longer duration.

Our study results also demonstrated that asthma exacerbations were significantly higher in patients having uncontrolled asthma. Another study also reported that exacerbation in last 12 months is a significant risk factor for poor asthma control.\textsuperscript{4} Asthma exacerbations have a negative impact on quality of life and are a source of burden on healthcare. Therefore, intense management should be addressed for its management and prevention of future exacerbations.

Our study has shown that proportion of patients not using ICS was significantly high in cases of uncontrolled asthma. Another study has reported that patients reported good asthma control with the consistent use of ICS.\textsuperscript{4} ICS has a good role in management of asthma by reducing its symptoms and improving quality of life by reducing the number of exacerbations, asthma related hospitalizations and improving pulmonary function. In addition, our study has further shown that excessive use of SABA was significantly higher in patients with uncontrolled asthma, a finding also reported by other studies.\textsuperscript{5,6} Use of short acting beta agonist as a rescue is a marker for severity of asthma and its high rate in uncontrolled asthma could suggest that the patients might not be using the maintenance medications or the dosage of the maintenance medications might not be enough.

Our study is not without certain limitations. First of all, this study was undertaken on a small sample size. Another limitation of this study was that some patients reported use of herbal medications for asthma control, and the content of such medicines is obscured. It may contain bronchodilator or steroids which remain unrevealed, so this may have certain impact on symptom control which couldn't be highlighted in the present study. Another limitation is that spirometry wasn't done in every patient labeled as having asthma, some patients were physician diagnosed so this may raise query on asthma diagnosis of such patients. Moreover many patients reported to have asthma may have persistent airflow limitation or asthma chronic obstructive pulmonary disease (COPD) overlap (ACO) which requires spirometry for differentiation.

These limitations aside, we believe to the best of our knowledge that this study was the initial step in determining the level of asthma control in a developing country like Pakistan. Moreover, factors associated with poor asthma control were also evaluated. It is recommended that further studies on larger sample size should be carried out.

CONCLUSION

A high proportion of patients had uncontrolled asthma in our population. Level of uncontrolled asthma was significantly higher in patients with incorrect inhaler usage technique, GERD, duration of symptoms more than 10 years, more than 1 episode of asthma exacerbation in past 12 months, absent use of ICS and high use of SABA.

ETHICAL APPROVAL: Liaquat College of Medicine and Dentistry Darul Sehat Hospital Karachi, Pakistan.

AUTHORS’ CONTRIBUTION: WR: Study design & concept, designed the Questionnaire, collected the data and performed data analysis. RNK: Study design & concept, drafting the manuscript, approved the final manuscript.

CONFLICT OF INTEREST: None.

FUNDING: None.

Received: October 18, 2020
Accepted: December 15, 2020

REFERENCES

1. Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol 2017; 17:99-103. doi: 10.1097/ACI.0000000000000346.
2. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-78. doi: 10.1111/j.1398-9995.2004.00526.x.
3. Kang HR, Song HJ, Nam JH, Hong SH, Yang SY, Ju S, et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open 2018 22; 8:e020825. doi: 10.1136/bmjopen-2017-020825.
4. Lin J, Wang W, Chen P, Zhou X, Wan H, Yin K, et al. Prevalence and risk factors of asthma in mainland China: The CARE study. Respir Med 2018; 137:445-54. doi:10.1016/j.rmed.2018.02.010.
5. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003; 45:1234-46. doi:10.1097/01.jom.0000999999.27348.78.
6. Gebremariam TH, Bindegdie AB, Mitiku AS, Ashagrie AW, Gebrehiwot KG, Huluka DK, et al Level of asthma
control and risk factors for poor asthma control among clinic patients seen at a Referral Hospital in Addis Ababa, Ethiopia. BMC Res Notes 2017; 10:558. doi: 10.1186/s13104-017-2887-2.

7. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24:14009. doi: 10.1038/njpccr.2014.9.

8. Demoly P, Anunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21:66-74. doi: 10.1183/09059180.0000811.

9. Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, et al. Assessment of asthma control in primary care. Curr Med Res Opin 2009; 25:2523-31. doi: 10.1185/03007990903218655.

10. Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. LIAISON Study Group. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res 2016; 17:51. doi: 10.1186/s12931-016-0374-z.

11. Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, et al. Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines. Wien Klin Wochenschr 2016; 128(15-16):541-54. doi:10.1007/s00050-016-1019-4.

12. Paasche-Orlow MK, Riekert KA, Bilderback A, Chanmugam A, Hill P, Rand CS, et al. Tailored education may reduce health literacy disparities in asthma self-management. Am J Respir Crit Care Med 2005; 172:980-6. doi: 10.1164/rcrm.200409-1291OC.

13. Bousquet J, Kiley J, Bateman ED, Viegi G, Cruz AA, Khaltava N, et al. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010; 36:995-1001. doi: 10.1183/09031936.00012610.

14. Gebremariam TH, Sherman CB, Schlugner NW. Perception of asthma control among asthmatics seen in Chest Clinic at Tertiary Hospital, Addis Ababa, Ethiopia. BMC Pulm Med 2019; 19:187. doi: 10.1186/s12890-019-0959-7.

15. Marchioro J, Gazzotti MR, Nascimento OA, Montealegre F, Fish J, Jardim JR. Level of asthma control and its relationship with medication use in asthma patients in Brazil. J Bras Pneumol 2014; 40:487-94. doi: 10.1590/s1806-37132014000500004.

16. Torchyan AA. Asthma control in Saudi Arabia: Gender implications. Allergy Asthma Proc 2017; 38:47-53. doi: 10.2500/aap.2017.38.4035.

17. Abrahamsen R, Gundersen GF, Svendsen MV, Klepaker G, Kongerud J, Fell AKM. Possible risk factors for poor asthma control assessed in a cross-sectional population-based study from Telemark, Norway. PLoS One 2020; 15:e0232621.

18. Zein JG, Erzurum SC. Asthma is Different in Women. Curr Allergy Asthma Rep 2015; 15:28. doi: 10.1007/s11882-015-0528-y.

19. Haselkorn T, Szefler SJ, Simons FE, Zeiger RS, Mink DR, Chippis BE, et al. TENOR Study Group. Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR. Pediatr Allergy Immunol 2010; 21:1157-65. doi: 10.1111/j.1399-3038.2010.01065.x.

20. Bednarek A, Bodajko - Grochowska A, Bartkowiak-Emeryk M, Klepacz R, Ciołkowski J, Zarzycka D, et al. Demographic and medical factors affecting short-term changes in subjective evaluation of asthma control in adolescents. Postepy Dermatol Alergol 2018; 35:259-66. doi: 10.5114/pdal.2018.76221.

21. Hekking PP, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in Difficult-to-Control Asthma. J Allergy Clin Immunol Pract 2018; 6:108-13. doi: 10.1016/j.jaip.2017.06.008.

22. Baffi CW, Wood L, Winnica D, Strollo PJ Jr, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest 2016; 149:1525-34. doi: 10.1016/j.chest.2015.12.034.

23. Lin J, Gao J, Lai K, Zhou X, He B, Zhou J, et al. The characteristic of asthma control among nasal diseases population: Results from a cross-sectional study. PLoS One 2018; 13:e0191543. doi: 10.1371/journal.pone.0191543.

24. Agondi RC, Andrade MC, Takejima P, Aun MV, Kallí J, Giavina-Bianchi P. Atopy is associated with age at asthma onset in elderly patients. J Allergy Clin Immunol Pract 2018; 6):865-71. doi: 10.1016/j.jaip.2017.10.028.

25. Chogtu B, Holla S, Magazine R, Kamath E. Evaluation of relationship of inhaler technique with asthma control and quality of life. Indian J Pharmacol 2017; 49:110-5. doi: 10.4103/0253-7613.201012.

26. Harnett CM, Hunt EB, Bowen BR, O’Connell OJ, Edgeworth DM, Mitchell P, et al. A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic. J Asthma 2014; 51:440-5. doi: 10.3109/02770903.2013.876650.

27. Jaimchariyatam N, Wongtim S, Udompanich V, Sittipanich S, et al. Predictive Factors in Adult Asthma Patients. J Clin Appl Res 2015; 9:610-3. doi: 10.3109/02770903.2013.876650.